Business Wire

Anomali Appoints Justin Coker as Vice President and General Manager of EMEA to Drive Growth Across Europe and the Middle East

16.12.2021 13:00:00 EET | Business Wire | Press release

Share

Anomali, the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that multi-decade industry veteran Justin Coker has been named Vice President and General Manager of Europe and the Middle East (EMEA). Coker takes the region’s helm during a period of explosive demand for Anomali’s leading cybersecurity solutions, which are delivering unmatched ability in precision threat detection and comprehensive response that stops immediate and future breaches and attacks.

“Anomali is building a world-class leadership team as we continue on our phenomenal growth trajectory around the world. Justin brings a powerful combination of experience and skill to ensure that our public and private sector customers and partners receive the attention needed to build efficient, high-performance security infrastructures that stop advanced breaches and the attackers targeting their enterprises,” said Ahmed Rubaie, CEO, Anomali. “We are excited to welcome Justin to the company; his commitment to the organization and regional expertise makes him the perfect leader for the job.”

Coker has spent more than 20 years in senior sales management roles at leading enterprise cybersecurity companies. He joins Anomali from IronNet Cybersecurity, where, as VP of EMEA, he built out a sales team from the ground up on its journey to its recent IPO. Prior to then, he was VP of EMEA at Skybox Security, where he grew the business from a start-up to a team of 50, along the way winning a comprehensive list of EMEA's largest organizations as customers and creating strong alliances with many of the premier partner organizations across the region. Before that, while at Symantec, he led the United Kingdom’s and Ireland's retail banking and finance enterprise sales team for five years. He has held other successful IT sales positions at AXENT Technologies, Parametric Technology, and Fujitsu. Throughout his professional career, Coker has exceeded expectations at building and scaling successful sales teams and has remained enthusiastic about delivering business value to his clients and partners.

“I am excited to be joining Anomali at such a pivotal phase of growth and innovation. I look forward to driving our deeper portfolio adoption across EMEA through the development of existing and new markets, coupled with the continued expansion of our global channel and technology partner ecosystem,” said Coker. “Anomali’s go-to-market approach in EMEA is centered around our continued passion for creating strong partnerships with our global enterprise clients and helping them capitalize upon significant business value. I look forward to fulfilling our mission to strengthen customers’ security efficacy and efficiency, fueled by our intelligence-driven detection and response solutions and world-class customer-focused team.”

Coker and his team will be furthering access to the award-winning Anomali portfolio, which includes ThreatStream, our leading threat management platform, Lens, the industry’s only Natural Language Processing (NLP) product that identifies all threats and IOCs in any web content to operationalize them across security infrastructures, and Match, our advanced global attacker detection and response solution that quickly identifies and responds to threats in real-time by automatically correlating all security telemetry data against active threat intelligence.

Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
Detect LIVE Conference: https://www.anomali.com/detect-live

About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management and refined by artificial intelligence and machine learning, the Anomali platform delivers proprietary capabilities that correlate an extraordinary volume of telemetry from customer-deployed security solutions with the largest repository of global intelligence, empowering security operations teams to detect threats with precision, optimize response, achieve resiliency, and stop attackers and breaches. Our Cloud-first SaaS-based solutions easily integrate into existing security tech stacks and accommodate hybrid deployments. Founded in 2013, Anomali serves public and private sector organizations, ISACs, MSSPs, and Global 1000 customers worldwide in every major industry. Leading venture firms including Google Ventures, General Catalyst, and IVP back Anomali. Learn more at www.anomali.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Joe Franscella
news@anomali.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release

Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye